University-Industry Engagement Week

Emory U and Genuity Science enter research deal on database to speed drug discovery

By Jesse Schwartz
Published: January 12th, 2021

Emory University and data and analytics company Genuity Science have signed a research  collaboration focused on developing Genuity’s population clinicogenomic database, with an initial focus on neurodegenerative disease. The database aims to enable research with pharma and biotech partners by speeding drug target and biomarker discovery and validation. It will also be used in patient stratification for clinical trial optimization in Genuity’s research efforts.

Emory’s Department of Neurology has one of the most advanced translational neuroscience research programs in the U.S. Allan Levey, MD, PhD, chairman of Emory’s Department of Neurology and director of its Goizueta Alzheimer’s Disease Research Center, noted that “more than five million Americans of all ages have Alzheimer’s and another million people in the U.S. alone are impacted by Parkinson’s. We know there are dozens of genes contributing to risk of these conditions. I believe there’s huge scope to improve drug discovery, development and clinical trials stemming from the insights Genuity hope to derive from this research. Our collaboration with Genuity provides us with a potential opportunity to greatly accelerate our academic research efforts for the benefit of our patient population by including whole genome sequence data to our cohort.”

Jeff Gulcher MD, PhD, Genuity’s chief scientific officer, said Emory “fits perfectly within our strategy of combining detailed clinical and longitudinal data from large-scale, powered cohorts of many thousands of patients with whole genome sequence and other omic data to provide discoveries beyond the usual suspects of disease genes. We can be an important partner in helping Emory pursue its mission to find more effective neurological treatment options for patients in the US and across the world living with these conditions.”

Boston-based Genuity partners with global biopharma and life sciences companies to offer end-to-end drug target and biomarker discovery programs.

Source: Cision

Posted under: University-Industry Engagement Week